Answers are grounded in this paper and cite their sources.
Shows no improvement in recurrence-free survival with vibostolimab in melanoma, suggesting ineffective combination therapy.
This news section offers Cancer readers timely information on events, public policy analysis, and topical issues. In this issue, the coformulation of vibostolimab with pembrolizumab did not improve recurrence‐free survival in comparison with pembrolizumab alone in patients with resected stage IIB–IV melanoma. In addition, the use of AI–supported mammography improved screening performance for the detection of interval breast cancers in comparison with standard double reading, and first‐line use of CDK4/6 inhibitors did not improve overall survival in comparison with second‐line use in patients with advanced breast cancer.
No takes yet. Share an insight, caveat, or question.
Leah Lawrence (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: